Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Radiation Oncology
•
Pediatric Oncology
•
Germ Cell Tumors
•
AYA
When does radiotherapy play a role in treatment of metastatic yolk sac germ cell tumor in an adolescent/young adult patient?
Related Questions
Which patients with relapsed/refractory NHL are appropriate for pre-CAR-T bridging radiation therapy?
Should all patients with a remote history of immunotherapy, chemotherapy and/or radiation therapy have a baseline TTE regardless of ASCVD risk?
Is there evidence to support or argue against intermittent fasting for cancer patients?
What are the key local therapy considerations for patients with malignant pleural effusion, bulky pleural disease, lung metastases and chest wall/diaphragm primary in a patient with Rhabdomyosarcoma or Ewing Sarcoma?
How soon after CAR T-cell therapy can salvage radiation be delivered?
How would you manage a patient less than 40 years old with an incidentally found LGG, IDH mutated, 1p19q intact, s/p STR?
Would you consider a cycle of EP in a patient with good risk stage IIIB seminoma on BEP but with bleomycin omitted for cycle 3?
How do you approach delivering ISRT to nodular lymphocyte predominant Hodgkin Lymphoma that has responded on FDG-PET/CT after chemotherapy?
What are magic mouthwash alternatives that you would recommend?
How do you manage severe hypertriglyceridemia in the adolescent & young adult population receiving chemotherapy for ALL, in the absence of complications related to hypertriglyceridemia?
